Skip to the care notes
The Texas care notebook
Before the offer
# A name is a start. It is not the answer.
Peptide care can sound like a single treatment. Start by asking which medicine is being discussed and what problem it is meant to address.
As of September 2026.
A few words, made clear
The Food and Drug Administration reviews medicines as a federal agency; FDA is its short name. An active ingredient is what gives a medicine its effect.
Get clear
## Peptide describes what it is
A peptide links protein building parts in a small chain. Insulin belongs to this group.
As of September 2026, US drug rules do not approve peptide care as a whole. Approval concerns a named medicine and what it is used to treat.
The useful next question is the product's exact name. A broad label such as wellness or peptide care does not tell you that name.
Read the source note
Source text
FDA explanation of compounding
Look closer
## Approval belongs to a product
As of September 2026.
FDA-approved medicines include Ozempic and Wegovy, which contain semaglutide, and Mounjaro and Zepbound, which contain tirzepatide. Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy and Zepbound are approved for weight loss.
Approval is for a particular medicine and use. It does not cover everything called a peptide.
Ask which problem the medicine would address and whether you would take it as a pill or a shot.
Read the source note
Source text
FDA semaglutide label
FDA tirzepatide label
Keep asking
## Made to order is another path
As of September 2026.
Compounding is the making or mixing of a medicine for a patient's needs by a pharmacist or doctor.
The resulting medicine is not FDA-approved, even when the pharmacy holds a state licence.
Making a medicine to order may be allowed when no approved medicine can meet a patient's medical need. The person making it must still meet the compounding rules.
Read the source note
Source text
FDA on the role of compounding
Carry it forward
## Research wording needs a closer look
As of September 2026.
FDA warns that when weight-loss products carry research labels and are offered to people, their quality is unknown and they could cause harm.
A care visit does not remove this warning about a research-labelled product. Ask the clinician about that exact product, including its research label.
Read the source note
Source text
FDA concerns about research products
Check the medicine's status
Your next page
## Turn to the Texas rules
Match the care setting with the checks that matter here.
## Turn to the Texas rules
This notebook helps you think through care choices; it does not provide clinic care or sell medicines.
Official tools All notebook pages Read as text
Start
Texas
Checks
Costs
Notebook